Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial ribosomal protein S26 is a component of the small 28S subunit of the mammalian mitochondrial ribosome (mitoribosome)[1]. It is encoded by nuclear DNA and imported into the mitochondria, where it contributes to the synthesis of mitochondrial-encoded proteins required for oxidative phosphorylation[1]. Mitoribosomes differ from cytoplasmic and prokaryotic ribosomes in protein/rRNA ratio and sequence divergence. MRPS26 is essential for the assembly and function of the mitoribosome, and defects in the gene are associated with rare mitochondrial diseases, particularly affecting respiratory chain function[1][4]. Like other ribosomal proteins, it may play roles in the regulation of cell growth and apoptosis, although these functions are less well-characterized for mitochondrial ribosomal proteins compared to cytoplasmic ones[2]. If you are seeking a molecular therapeutic target, it is important to note that MRPS26 is not currently recognized as a drug target, and there are no drugs or established mechanisms of action directly related to this protein. It is best classified as an essential structural protein involved in mitochondrial protein synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial ribosomal protein S26 (MRPS26).